The Association of the British Pharmaceutical Industry (ABPI) has revealed that there are a number of new treatments for Alzheimer's "in the pipeline".
Richard Barker, director general of the association, stated that the industry is developing medications which, while not preventing the condition, can at least "slow the process down".
This could lead to sufferers leading "longer, more useful, more satisfying lives", he added.
Mr Barker's comments come after a survey conducted by the ABPI to identify which illnesses the British public believe should be a priority for national health spending, enabling the ABPI to determine whether treatments in the research and development pipeline match the public and the NHS' s agenda.
Alzheimer's was found to be the third most cited disease after cancer and heart disease, with 11 per cent of the public demanding greater national health spending and 12 per cent more research.
According to the Alzheimer's Society, delaying the onset of dementia by 5 years would reduce deaths directly attributable to dementia by 30,000 a year.
Please click here for advice to help find the right type of care.